Vaccines that stimulate T cell immunity to HIV-1: The next step

Nature Immunology

Volumn 15, Issue 4, 2014, Pages 319-322

  Mcmichael, Andrew J ^a   Koff, Wayne C ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MONKEY MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

AIDS VACCINES; ANIMALS; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HAPLORHINI; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; PROTEIN ENGINEERING; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84897877845     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2844     Document Type: Review

References (35)

1. Haynes, B.F. & McElrath, M.J. Progress in HIV-1 vaccine development. Curr. Opin. HIV AIDS 8, 326-332 (2013.
2. Verkoczy, L., Kelsoe, G., Moody, M.A. & Haynes, B.F. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 23, 383-390 (2011.
3. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009.
4. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012.
5. McMichael, A.J., Borrow, P., Tomaras, G.D., Goonetilleke, N. & Haynes, B.F. The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. 10, 11-23 (2010.
6. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-Augmented DNA vaccination. Science 290, 486-492 (2000.
7. McElrath, M.J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 372, 1894-1905 (2008.
8. Hammer, S.M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083-2092 (2013.
9. Hansen, S.G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011.
10. Hansen, S.G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013.
11. Hansen, S.G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013.
12. Lee, J.K. et al. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200, 1455-1466 (2004.
13. Liu, M.K. et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J. Clin. Invest. 123, 380-393 (2013.
14. Rolland, M. et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17, 366-371 (2011.
15. Korber, B.T., Letvin, N.L. & Haynes, B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83, 8300-8314 (2009.
16. Santra, S. et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16, 324-328 (2010.
17. Barouch, D.H. et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16, 319-323 (2010.
18. Stephenson, K.E. et al. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J. Virol. 86, 11434-11440 (2012.
19. Létourneau, S. et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2, e984 (2007.
20. Rolland, M., Nickle, D.C. & Mullins, J.I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 3, e157 (2007.
21. Mothe, B. et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J. Transl. Med. 9, 208 (2011.
22. Goonetilleke, N. et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-And modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80, 4717-4728 (2006.
23. Borthwick, N. et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol. Ther. 22, 464-475 (2014.
24. Kiepiela, P. et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46-53 (2007.
25. Barouch, D.H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012.
26. Parks, C.L., Picker, L.J. & King, C.R. Development of replication-competent viral vectors for HIV vaccine delivery. Curr. Opin. HIV AIDS 8, 402-411 (2013.
27. Mothe, B. et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE 7, e29717 (2012.
28. Spentzou, A. et al. Viral inhibition assay: A CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201, 720-729 (2010.
29. Yang, H. et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis. 206, 552-561 (2012.
30. Freel, S.A. et al. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J. Virol. 86, 6835-6846 (2012.
31. Almeida, J.R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473-2485 (2007.
32. Berger, C.T. et al. High-functional-Avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J. Virol. 85, 9334-9345 (2011.
33. Shapiro, S.Z. Clinical development of candidate HIV vaccines: Different problems for different vaccines. AIDS Res. Hum. Retroviruses doi:10.1089/aid.2013.0114 (22 November 2013.
34. Pereyra, F. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551-1557 (2010.
35. Alizon, S. et al. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog. 6, e1001123 (2010.